These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36601737)

  • 21. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
    Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
    Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
    Jacobson PA; Huang J; Wu J; Kim M; Logan B; Alousi A; Grimley M; Bolaños-Meade J; Ho V; Levine JE; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):421-9. PubMed ID: 19925875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Itacitinib prevents xenogeneic GVHD in humanized mice.
    Courtois J; Ritacco C; Dubois S; Canti L; Vandenhove B; Seidel L; Daulne C; Caers J; Servais S; Beguin Y; Ehx G; Baron F
    Bone Marrow Transplant; 2021 Nov; 56(11):2672-2681. PubMed ID: 34172892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
    Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
    Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
    Zeiser R; von Bubnoff N; Butler J; Mohty M; Niederwieser D; Or R; Szer J; Wagner EM; Zuckerman T; Mahuzier B; Xu J; Wilke C; Gandhi KK; Socié G;
    N Engl J Med; 2020 May; 382(19):1800-1810. PubMed ID: 32320566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
    Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
    Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
    Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
    Watkins B; Qayed M; McCracken C; Bratrude B; Betz K; Suessmuth Y; Yu A; Sinclair S; Furlan S; Bosinger S; Tkachev V; Rhodes J; Tumlin AG; Narayan A; Cribbin K; Gillespie S; Gooley TA; Pasquini MC; Hebert K; Kapoor U; Rogatko A; Tighiouart M; Kim S; Bresee C; Choi SW; Davis J; Duncan C; Giller R; Grimley M; Harris AC; Jacobsohn D; Lalefar N; Norkin M; Farhadfar N; Pulsipher MA; Shenoy S; Petrovic A; Schultz KR; Yanik GA; Waller EK; Levine JE; Ferrara JL; Blazar BR; Langston A; Horan JT; Kean LS
    J Clin Oncol; 2021 Jun; 39(17):1865-1877. PubMed ID: 33449816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of anti-anaerobic antibiotic activity on graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling.
    Hanks CR; Slain D; Kanate AS; Wen S; Cumpston A
    Transpl Infect Dis; 2021 Aug; 23(4):e13676. PubMed ID: 34165853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
    Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
    J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
    Phillips TJ; Forero-Torres A; Sher T; Diefenbach CS; Johnston P; Talpaz M; Pulini J; Zhou L; Scherle P; Chen X; Barr PM
    Blood; 2018 Jul; 132(3):293-306. PubMed ID: 29695516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.